Clinical-stage biotech developing new products for highly prevalent issues and diseases using the unique strengths of a novel platform organism
Seattle, WA
Joined April 2017
- Tweets138
- Following35
- Followers350
- Likes35
Lumen Bioscience retweeted
New piece from me and @KevinKlowden in BioCentury today.
“The future of biotech is preventive — and global”
Lumen Bioscience retweeted
From $100 a gram to 10 cents, #antibody production is having a revolution!
Seattle-based @LumenBio, led by CEO Brian Finrow, is developing a method to produce antibodies in edible spirulina, drastically lowering costs and enabling oral administration: bit.ly/4oyZqYe
Lumen Bioscience retweeted
That’s probably the most common question we get. Loads of information on the advantages and limitations of the technology here in our platform paper:
nature.com/articles/s41587-0…
Lumen Bioscience retweeted
Sure, extraordinary claims demand, extraordinary evidence. Fair enough.
That said, while this is pending confirmation in the now-running phase 3 study, but we are encouraged by these preliminary results below:
contagionlive.com/view/inves…
Lumen Bioscience retweeted
This Seattle co. says it can take the price of making mAbs/antibody drugs from $100/g to less than $0.10/g by growing them in a type of edible algae — and the Pentagon and Gates Foundation are listening endpoints.news/pentagon-back…
Lumen Bioscience retweeted
.@rossry doesn't ask easy questions—he asks the right ones.
Honored to be an early guest on the new @DevAndResearch interview series, where we dug deep on what makes drug development tick.
We're back with @DevAndResearch, where I spoke with @Finrow on:
• why we should grow more drugs in algae, and fewer in Chinese Hamster Ovary cells,
• why "monoclonal antibodies" are particularly safe and effective as drugs—but incredibly expensive to manufacture,
• and whether the fundamental problem of the biotech industry is that everyone just has too much money.
Timestamps:
01:17 What makes a molecule a drug?
04:48 What’s so great about antibody drugs?
05:59 The humble Chinese Hamster Ovary cell
11:27 Introducing: Lumen Biosciences
12:40 Why spirulina?
19:14 Why isn't everyone doing this?
23:53 Going after gut infections
33:44 “Cocktails” of protein drugs
50:25 Other diseases of outside-of-body lumens
01:04:36 How to run a different breed of biotech
01:17:44 “Everyone just has too much money”
01:21:07 Extinction events in the biotech industry…and “little mammals scurrying around”
01:24:28 Speculations about the future (for Lumen and the world of direct-to-consumer drugs)
Lumen Bioscience retweeted
Good or bad, when institutions are remade it's an opportunity for fresh new ideas to root.
There's plenty of negative criticism out there—from all sides—but @innovationwonk and I jotted down some constructive ideas to throw into the mix—published here in @statnews
Lumen Bioscience retweeted
I wish I were as good as @brianbuntz at distilling complex science into a simple story.
The piece he published yesterday on our LMN-201 product captures the full story in just 750 words, including a fair amount of technical detail.
Impressive!
Lumen Bioscience retweeted
This was tons of fun.
IMO, @mattpillar is the best podcast host in biotech.
lnkd.in/gXZhFj85
Lumen Bioscience retweeted
New piece on @LumenBio by @brianbuntz over at Drug Discovery & Development — covers an incredible amount of ground in short order.
If we haven't been talking as much publicly the past 6 months, it's just because we've had our heads down, pushing these (many) programs forward.
Watch this space.
drugdiscoverytrends.com/lume…
Lumen Bioscience retweeted
Excited to share our new paper using AlphaSeq data to enable predictive ML models for antibody engineering with our wonderful collaborators at @Google and @LumenBio
biorxiv.org/content/10.1101/…
Lumen Bioscience retweeted
New piece from me in @BioProcessIntl today (link below).
It's clear that rising complexity is a drives escalating costs in clinical trials, but can simplification help with other segments of the new-drug product development process?
bioprocessintl.com/upstream-…
Lumen Bioscience retweeted
Happening now: First Opinion editor @thekibosch hosts a conversation about antibiotic resistance on STAT+ Connect. trib.al/E7cvJYq
ALT A teal graphic reads "First Opinion Deep Dive: A Company's Novel Approach to Antibiotic Resistance with Brian Finrow, Founder and CEO, Lumen Bioscience. Hosted By Torie Bosch. RSVP on STAT+ Connect"
Lumen Bioscience retweeted
.@Finrow, founder and CEO of Lumen Bioscience, will discuss his company's novel approach to antibiotic resistance, the biopharma industry, and more with STAT's @thekibosch in the next STAT+ Connect conversation. Learn more: trib.al/2Q1L3py
ALT A teal graphic reads "First Opinion Deep Dive: A Company's Novel Approach to Antibiotic Resistance with Brian Finrow, Founder and CEO, Lumen Bioscience. Hosted By Torie Bosch. RSVP on STAT+ Connect"
Lumen Bioscience retweeted
Have you joined STAT+ Connect yet? Become a subscriber today and enjoy exclusive conversations with editors, reporters and more.
Next week, @thekibosch will talk to @Finrow about his company's novel approach to antibiotic resistance. Learn more: trib.al/w5qw5Sh
Lumen Bioscience retweeted
.@LumenBio is the inaugural winner of the $1.5 million @WilkesCenter Climate Prize!
Lumen Bioscience's proposal would drastically reduce methane emissions from cattle—which contribute 25% of global warming—using a patented mixture of enzyme proteins.
📰 attheu.utah.edu/facultystaff…
Lumen Bioscience retweeted
.@LumenBio CEO @Finrow discusses his company's investigational #cdiff therapy being studied for prevention and treatment of the healthcare-associated infection. #IDtwitter #MedTwitter
contagionlive.com/view/inves…
Lumen Bioscience retweeted
#LSINW23 – Clinical development costs have ballooned so rapidly that they threaten the industry’s financial viability. Brian Finrow (@LumenBio) discusses advancements that could make changes in clinical development costs w/ Tanya Chiatovich, Theresa Deisher, PhD, and Scott Dixon.
